TSO3 (TOS.TO) – Is this the bottom?

Themoneynarrative publishes report cards for all recommendations.  TSO3 has been our worst performer after three months, by far, where we deservedly scored an “F” [see themoneynarrative 3-month report card – TSO3 (TOS.TO)].  Our timing turned out to be terribly wrong,

TSO3 (TOS.TO) – average down recommendation

Original company recommendation publication date: November 3, 2017 (see TSO3 (TOS.TO))
Recommendation: Buy at current market, on dips.
Acquisition price: $2.535 (see themoneynarrative report card – TSO3 (TOS.TO))

themoneynarrative 3-month report card – TSO3 (TOS.TO)

Report publication date: November 3, 2017
Recommendation: Buy at current market, on dips.
Prior trading day (November 2, 2017) price close: $2.695
Report date (November 3, 2017) trading range: $2.66 – $2.72

TSO3 (TOS.TO) – an update

Yesterday (January 25, 2018) morning, TOS.TO issued a press release during market hours (preceded by a trading halt pending news) outlining a new arrangement it has entered into with its global distribution partner, Getinge Infection Control AB (Getinge).

themoneynarrative report card – TSO3 (TOS.TO)

Report publication date: November 3, 2017
Recommendation: Buy at current market, on dips.
Prior trading day (November 2, 2017) price close: $2.695
Report date (November 3, 2017) trading range: $2.66 – $2.72

TSO3 (TOS.TO)

TOS.TO is a medical-device sterilization company that has a breakthrough technology enabling full sterilization of hard-to-sterilize medical instruments (primarily scopes).  This may not seem like a big deal, but the number of infections and even deaths caused by improperly cleaned medical equipment is astonishingly high.  The related health costs